The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects

Immunology of Relapse and Remission in Multiple Sclerosis

(2014) Lawrence Steinman   Annual Review of Immunology

Intrathecal Rituximab Therapy in Multiple Sclerosis: Review of Evidence Supporting the Need for Future Trials

(2014) Mickael Bonnan et al.   CURRENT DRUG TARGETS

Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: A phase 2 study

(2014) P. S. Sorensen et al.   NEUROLOGY

Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program

(2014) Paul Emery et al.   PLoS One

Efficacy and Safety of Ocrelizumab in Active Proliferative Lupus Nephritis: Results From a Randomized, Double-Blind, Phase III Study

(2013) Eduardo F. Mysler et al.   ARTHRITIS AND RHEUMATISM

Reduced T-Dependent Humoral Immunity in CD20-Deficient Mice

(2013) D. E. D. Morsy et al.   JOURNAL OF IMMUNOLOGY

Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression

(2013) Jeppe Romme Christensen et al.   PLoS One

Rituximab in Relapsing and Progressive Forms of Multiple Sclerosis: A Systematic Review

(2013) Tamara Castillo-Trivino et al.   PLoS One

Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects

(2013) Nikolaos A. Patsopoulos et al.   PLoS Genetics

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

(2012) P. P. Tak et al.   ARTHRITIS AND RHEUMATISM

The evidence for a role of B cells in multiple sclerosis

(2012) G. Disanto et al.   NEUROLOGY

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

(2011) M. H. Buch et al.   ANNALS OF THE RHEUMATIC DISEASES

Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial

(2011) P. C. Taylor et al.   ANNALS OF THE RHEUMATIC DISEASES

Follicular Helper CD4 T Cells (TFH)

(2011) Shane Crotty   Annual Review of Immunology

Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial

(2011) W. Rigby et al.   ARTHRITIS AND RHEUMATISM

Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study

(2011) W. G. Wierda et al.   BLOOD

Treatment of multiple sclerosis with Anti-CD20 antibodies

(2011) Barbara Barun et al.   CLINICAL IMMUNOLOGY

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial

(2011) Ludwig Kappos et al.   LANCET

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

(2011) Ludwig Kappos et al.   Multiple Sclerosis Journal

Review: The architecture of inflammatory demyelinating lesions: implications for studies on pathogenesis

(2011) H. Lassmann   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Fatal progressive multifocal leukoencephalopathy in a patient with non-Hodgkin lymphoma treated with rituximab

(2010) Jakob Paues et al.   JOURNAL OF CLINICAL VIROLOGY

Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS?

(2009) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?

(2009) Howard L. Weiner   ANNALS OF NEUROLOGY

Progressive multifocal leukoencephalopathy: A national estimate of frequency in systemic lupus erythematosus and other rheumatic diseases

(2009) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

New approaches of B-cell-directed therapy: beyond rituximab

(2009) Thomas Dörner et al.   CURRENT OPINION IN RHEUMATOLOGY

Rituximab in relapsing-remitting multiple sclerosis: A 72-week, open-label, phase I trial

(2008) Amit Bar-Or et al.   ANNALS OF NEUROLOGY

B-Cell Depletion with Rituximab in Relapsing–Remitting Multiple Sclerosis

(2008) Stephen L. Hauser et al.   NEW ENGLAND JOURNAL OF MEDICINE